Clinical study of effects of Qici Sanling Decoction on postoperative recurrence rate of patients with non-muscle invasive bladder cancer

YU Chao; CAO Hongwen; CHEN Lei; HE Xiaofeng; FENG Yigeng; ZHAO Youkang; ZENG Rongcai; GONG Hua

doi:10.16305/j.1007-1334.2018.07.012

您当前的位置：

首页 >

文章列表页 >

Clinical study of effects of Qici Sanling Decoction on postoperative recurrence rate of patients with non-muscle invasive bladder cancer

更新时间：2022-08-31

- Clinical study of effects of Qici Sanling Decoction on postoperative recurrence rate of patients with non-muscle invasive bladder cancer
- Shanghai Journal of Traditional Chinese Medicine Vol. 52, Issue 7, Pages: 43-47(2018)
- 作者机构：
  
  1. 上海中医药大学附属龙华医院外一科,上海,200032
  2. 上海市周智恒名中医工作室,上海,200032
  3. 上海市中医泌尿男科临床示范基地,上海,200032
- 作者简介：
- 基金信息：
- DOI：10.16305/j.1007-1334.2018.07.012
  CLC：
扫描看全文
YU Chao, CAO Hongwen, CHEN Lei, et al. Clinical study of effects of Qici Sanling Decoction on postoperative recurrence rate of patients with non-muscle invasive bladder cancer. [J]. Shanghai Journal of Traditional Chinese Medicine 52(7):43-47(2018)
DOI：

YU Chao, CAO Hongwen, CHEN Lei, et al. Clinical study of effects of Qici Sanling Decoction on postoperative recurrence rate of patients with non-muscle invasive bladder cancer. [J]. Shanghai Journal of Traditional Chinese Medicine 52(7):43-47(2018) DOI： 10.16305/j.1007-1334.2018.07.012.

摘要

目的：观察芪慈三苓汤联合吡柔比星灌注治疗非肌层浸润性膀胱癌术后患者的临床疗效。方法：将100例TUR-Bt术后非肌层浸润性膀胱癌患者分为治疗组(66例)和对照组(34 例)。对照组予吡柔比星膀胱灌注方案,治疗组在对照组治疗措施基础上加服芪慈三苓汤治疗。两组疗程均为1年、随访1年,观察肿瘤复发情况及用药安全性,比较相关症状及生活质量量表评分(QLQ-C30及QLQ-BLS24子量表)、相关免疫功能指标(NK、CD4,+,及CD8,+,)的变化情况。结果：①治疗后1年内,治疗组、对照组总复发率分别为15.6%、25.0%,组间总复发率比较,治疗组明显低于对照组(P,<,0.05)。②治疗后组间比较,疲乏、疼痛、失眠、便秘、躯体功能、情绪功能及总体健康状况评分差异有统计学意义,治疗组改善情况明显优于对照组(P,<,0.05)。③组间治疗后比较,排尿症状、肠道症状、治疗相关问题、性生活质量评分差异有统计学意义,治疗组改善情况明显优于对照组(P,<,0.05)。④组间治疗后比较,NK、CD4,+,及CD8,+,的水平差异有统计学意义,治疗组改善情况明显优于对照组(P,<,0.05)。⑤两组不良反应发生率比较,差异无统计学意义(P,>,0.05)。结论：芪慈三苓汤联合吡柔比星灌注治疗非肌层浸润性膀胱癌术后患者,能明显降低肿瘤复发率,提高其全身免疫水平,减轻化疗药物灌注的副作用,提高其总体生活质量。

Abstract

Objective:To observe the clinical efficacy of Qici Sanling Decoction combined with Pirarubicin in the treatment of non-muscle invasive bladder cancer. Methods100 TUR-BT postoperative patients with non-muscle invasive bladder cancer were randomly divided into the treatment group(66 cases) and control group(34 cases). The control group was treated with Pirarubicin by intravesical instillation and the treatment group was orally treated with Qici Sanling Decoction based on the treatment for the control group,with a course of 1 year,and the patients were followed-up for 1 year after treatment. The tumor recurrence and medication safety were observed. The changes on correlative symptoms,life quality scale(QLQ-C30 and QLQ-BLS24 sub-scales),immune function indexes such as NK cells,CD4,+, and CD8,+, were compared. Results:①Within 1 year after treatment,the recurrence rates were 15.6% in the treatment group and 25.0% in the control group,the recurrence rate in the treatment group was obviously lower than that in the control group(P,<,0.05). ②After treatment,there were statistically significant differences on the scores of fatigue,pain,insomnia,constipation,physical function,emotional function and overall health condition between the two groups,and the improvement in the treatment group was obviously better than that in the control group(P,<,0.05). ③After treatment,there were statistically significant differences on the scores of urination symptoms,intestinal symptoms,treatment relative problems and sexual life quality between the two groups,and the improvement in the treatment group was obviously better than that in the control group(P,<,0.05). ④After treatment,there were statistically significant differences on the levels of NK cells,CD,4+, and CD,8+, between the two groups,and the improvement in the treatment group was obviously better than that in the control group(P,<,0.05). ⑤There was no statistically significant difference on the incidence rate of adverse reactions between the two groups(P,>,0.05). Conclusion:Qici Sanling Decoction combined with Pirarubicin in treating postoperative patients with non-muscle invasive bladder cancer can significantly reduce the cancer recurrence rate,enhance the systemic immunity,alleviate the side effects caused by chemotherapy drug instillation and improve the overall quality of life.

关键词

非肌层浸润性膀胱癌芪慈三苓汤术后复发减毒增效生活质量中医药

Keywords

non-muscle invasive bladder cancerQici Sanling Decoctionrecurrence after operationreducing toxicity and enhancing efficacyquality of lifetraditional Chinese medicine

references

Views

164

下载量

CSCD

CNKI被引量

Alert me when the article has been cited

提交

Tools

Publicity Resources

Xuanhushangtong Tablets combined with celecoxib in promoting rapid rehabilitation after distal radius fractures

Clinical observation on intervention effect of Baduanjin on pre⁃diabetic patients in the community

Research progress on traditional Chinese medicine regulating renin-angiotensin-aldosterone system in prevention and treatment of chronic heart failure

Clinical study on the effect of Yiqi Huayu Decoction on intracranial residual hematoma after chronic subdural hematoma surgery

Effects of Fuzheng Jiedu Granules on immune function and life quality of patients with non-small cell lung cancer during postoperative chemotherapy

Related Author

No data

Related Institution

Sichuan Province Orthopaecological Hospital

South District of Guang’anmen Hospital， China Academy of Chinese Medical Science

School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine

School of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine

Department of Neurosurgery, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

⁰